Management holds a conference call to discuss detailed interim data from the P2, Part 1 study evaluating BA3011 for Non-Small Cell Lung Cancer (NSCLC) on December 4 at 11 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCAB:
- BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
- BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
- BioAtla management to meet virtually with BTIG
- BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
- BioAtla to Participate in the Jefferies London Healthcare Conference
